958 results on '"le Coutre, Philipp"'
Search Results
152. Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial
153. Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population
154. Clinical Lessons to Be Learned from Patients Developing Chronic Myeloid Leukemia While on Immunosuppressive Therapy after Solid Organ Transplantation: Yet Another Case after Orthotopic Heart Transplantation
155. 4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients
156. GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome
157. 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
158. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study.
159. Impact of Donor Age on Outcome of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation in Complete Remission
160. A Rare Case of Acute Myeloid Leukemia with a t(2;3) Chromosomal Translocation Characterized by Thrombophilia and Chemoresistance
161. An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
162. Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
163. Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study
164. Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months
165. Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis
166. Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1
167. Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial
168. Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln für seltene Leiden gemäß § 35a SGB V und der Bewertung im IQWiG Bericht Nr. 181, veröffentlicht am 1. August 2013, Vorgangsnummer 2013-05-01-D-064
169. Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia
170. Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial
171. Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study
172. Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level
173. Role of [Alpha]1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-[ABL.sup.+] Leukemic Cells to the Abl Inhibitor STI571
174. Ponatinib in Heavily Pretreated Leukemia: 3-Year PACE Trial Results
175. Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.
176. Up-regulatedMSI2is associated with more aggressive chronic myeloid leukemia
177. MSI2 and HOXA9 Expression Is Significantly Increased in Patients with Primary Myelofibrosis
178. Frequency of a Highly Polymorphic Variant, S36N GFI1, Is Increased in CML Patients
179. Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd
180. The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis
181. MSI2 and TGFβR1 Expression Levels in CML Patients and Hematopoietic Cell Lines
182. Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
183. The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program
184. Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update
185. Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF)
186. Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial
187. BCR-ABL1+ Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1- Subclone as a Cause of Refractory Disease with Nilotinib Treatment
188. Differential expression ofSHP-1in chronic myeloid leukemia
189. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission
190. Comparison of Chimerism and Minimal Residual Disease Monitoring for Relapse Prediction after Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia
191. Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial
192. ASXL1Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
193. ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
194. Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients
195. Molekulare Therapie der chronischen myeloischen Leukämie
196. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
197. Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans
198. Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.
199. Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
200. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.